stocks logo

ARQT

Arcutis Biotherapeutics Inc
$
14.015
+0.315(+2.300%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.180
Open
13.500
VWAP
13.85
Vol
1.05M
Mkt Cap
1.63B
Low
13.435
Amount
14.50M
EV/EBITDA(TTM)
--
Total Shares
115.76M
EV
1.62B
EV/OCF(TTM)
--
P/S(TTM)
8.39
Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an established biological target in dermatology. It is also developing roflumilast cream for the treatment of atopic dermatitis. ZORYVE is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
84.50M
+18.41%
-0.087
-3.7%
78.26M
+74.86%
-0.110
-66.67%
70.91M
+129.79%
-0.153
-63.49%
Estimates Revision
The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 4.12% over the past three months. During the same period, the stock price has changed by 20.92%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-20.97%
In Past 3 Month
Stock Price
Go Up
up Image
+20.92%
In Past 3 Month
8 Analyst Rating
up Image
35.57% Upside
Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 19.00 USD with a low forecast of 15.00 USD and a high forecast of 21.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
up Image
35.57% Upside
Current: 14.015
sliders
Low
15.00
Averages
19.00
High
21.00
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-09
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-03
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$19
2025-04-03
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Reiterates
n/a
2025-04-03
Reason
Jefferies
Kambiz Yazdi
Strong Buy
Maintains
$16 → $19
2025-03-11
Reason
Jefferies raised the firm's price target on Arcutis Biotherapeutics to $19 from $16 and keeps a Buy rating on the shares. The firm views Arcutis as a beneficiary of a rotation to commercial from clinical biotech names given underlying market dynamics and market volatility shifting the risk profile lower, the analyst tells investors. Arcutis has demonstrated steady Zoryve growth and consistent quarterly beats, adds the analyst, who calls it a "GARP-y SMID-cap biotech."
Goldman Sachs
Jonathan Block
Hold
Maintains
$13 → $15
2025-02-27
Reason

Valuation Metrics

The current forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT.O) is -26.12, compared to its 5-year average forward P/E of -5.85. For a more detailed relative valuation and DCF analysis to assess Arcutis Biotherapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.85
Current PE
-26.12
Overvalued PE
-1.24
Undervalued PE
-10.46

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.66
Current EV/EBITDA
-19.89
Overvalued EV/EBITDA
-1.05
Undervalued EV/EBITDA
-8.27

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
183.91
Current PS
5.59
Overvalued PS
503.81
Undervalued PS
-135.99

Financials

Annual
Quarterly
FY2025Q1
YoY :
+32.84%
65.85M
Total Revenue
FY2025Q1
YoY :
-22.43%
-24.53M
Operating Profit
FY2025Q1
YoY :
-29.17%
-25.06M
Net Income after Tax
FY2025Q1
YoY :
-37.50%
-0.20
EPS - Diluted
FY2025Q1
YoY :
-1.95%
-30.99M
Free Cash Flow
FY2025Q1
YoY :
-7.32%
86.59
Gross Profit Margin - %
FY2025Q1
-54.83
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.3M
USD
17
3-6
Months
1.0M
USD
8
6-9
Months
1.7M
USD
13
0-12
Months
187.6K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
34.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.5M
Volume
4
6-9
Months
0.0
Volume
0
0-12
Months
2.3M
Volume
4
Bought
0-3
0
0.0
Volume
Months
3-6
4
955.9K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
10
11.6M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ARQT News & Events

Events Timeline

2025-05-07 (ET)
2025-05-07
11:21:22
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements
select
2025-05-06 (ET)
2025-05-06
16:04:03
Arcutis Biotherapeutics reports Q1 EPS (20c), consensus (21c)
select
2025-04-10 (ET)
2025-04-10
16:37:32
Arcutis Biotherapeutics CFO David Topper to retire, Latha Vairavan to succeed
select
Sign Up For More Events

News

9.5
05-06Yahoo Finance
PinnedArcutis Announces First Quarter 2025 Financial Results and Provides Business Update
9.5
05-06SeekingAlpha
PinnedArcutis Biotherapeutics GAAP EPS of -$0.20 beats by $0.02, revenue of $65.8M beats by $3.32M
9.0
05-07Newsfilter
PinnedArcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
Sign Up For More News

FAQ

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) stock price today?

The current price of ARQT is 14.015 USD — it has increased 2.3 % in the last trading day.

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s business?

arrow icon

What is the price predicton of ARQT Stock?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s revenue for the last quarter?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Arcutis Biotherapeutics Inc (ARQT)'s fundamentals?

arrow icon

How many employees does Arcutis Biotherapeutics Inc (ARQT). have?

arrow icon

What is Arcutis Biotherapeutics Inc (ARQT) market cap?